The billionaire fund manager cashed out of market hedges this week to the tune of $2.6 billion, and used that cash to buy these 6 stocks.
Read MoreTrade Setup Buy Target $0.98 Sell Target $1.22 Charles & Colvard, Ltd. manufactures, markets, and distributes moissanite jewels and finished jewelries worldwide. The company offers stud earrings, solitaire and three stone rings, pendants, and bracelets. It also provides colorless moissanite jewel with 27 cuts and in sizes ranging from .002 carats to 6.13 carats, under […]
Read MoreIf you’re like me, you can really only take so much of the daily commentary on any news media outlet that is entirely and completely fixed on COVID-19. That isn’t to minimize the importance of the crisis-level measures that, I think are appropriately being taken on a national scale to try to slow the spread […]
Read MorePlus, the Senate passed its $2 trillion coronavirus stimulus package, deaths from COVID-19 surpassed 1,000 in the U.S., and Wendy’s withdrew guidance for the year.
Read MoreBuy Target – $6.50 or better Sell Target – TradersPro Sell Signal Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste generated outside the hospital and health care facility settings; TakeAway Recovery System for […]
Read MoreTrade Setup Buy Target $60.15 Sell Target $70.57 Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor […]
Read MoreTrade Setup Buy Target $1.12 Sell Target $1.68 Extraction Oil & Gas, Inc., an independent oil and gas company, focuses on the acquisition, development, and production of oil, natural gas, and natural gas liquid reserves in the Rocky Mountain region, primarily in the Wattenberg Field of the Denver-Julesburg (DJ) Basin of Colorado.
Read MoreAt the beginning of my career in the financial industry, I was a licensed rep for one of the largest mutual fund and discount brokerage companies in North America. Looking over the mutual funds that we offered, and digging into their respective investment philosophies was something I found to be really fascinating. It wasn’t just […]
Read MoreBuy Target – $2.25 or better Sell Target – TradersPro Sell Signal Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company’s development stage drug candidates for cardiosphere-derived cells […]
Read MorePlus, 1 month and 3 month Treasury yields slipped into negative territory this morning, Target withdrew its full-year forecast, and Nike shares are rising after the sneaker maker reported better-than-expected sales.
Read MoreI often observe, and write about the need to try to filter through the “noise” of the market to find the right ways and places to put your money to work for you. A lot of that noise, of course comes from media outlets, including market news. The irony of my observation is that it […]
Read MoreBuy Target – $11.50 or better Sell Target – TradersPro Sell Signal BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics for conditions with high unmet medical need. Its lead drug candidate includes BLU-5937, a small molecule antagonist of the P2X3 receptor for chronic cough. The company also has economic interests in various partnered […]
Read MorePlus, the market is higher on optimism that a third stimulus bill will be finalized today, Gilead Sciences’ experimental COVID-19 treatment, remdesivir, received Orphan Drug Designation from the FDA, and General Motors said it is conserving cash and drawing down $16 billion from credit lines.
Read MoreTrade Setup Buy Target $4.59 Sell Target $5.88 Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase Ib clinical trials for advanced hematologic […]
Read MoreI had to chuckle this weekend a bit as I read some some market news reports. The market has dropped far enough that in the latter part of the week, I think investors were starting to look for reasons to start buying. Friday looked set to mark the first time in weeks the market managed […]
Read More